Bioavailability of BIBR 1048 MS Formulations With and Without Pantoprazole

Phase 1, randomised, open-label trial of dabigatran etexilate oral solution in thromboembolism (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Total amount of BIBR 953 ZW excreted into urine during one dosing interval and Area under the plasma concentration-time curve at steady state at Day 3. Started Feb 2002; status: completed.